Big impact in big pharma – WHEB | Pensions For Purpose

Only members with restricted access (ie. academics, asset owners, government and regulatory, independent advisers/trustees and sponsoring employers) can view this article. Please login or join to view.

The avid follower of WHEB’s investment strategies will have noticed a marked increase in exposure to so-called 'big pharma' stocks with CSL, Astra Zeneca and Genmab in their main strategy and Novo Nordisk additionally in their European Fund. Just a few years ago, WHEB had only minimal exposure for good reasons so what has changed?

To the extent that anything on this website constitutes a financial promotion it is exempt from the general prohibition in S21 of FSMA on the basis that the site is only intended for investment professionals as such term is defined in S19 of the Financial Promotions Order. Please note that Pensions for Purpose does not provide consultancy services, advice or personal recommendations on any of the investment opportunities mentioned on the platform. We curate content written by members and do not endorse any underlying funds.

Learn more here

Big impact in big pharma – WHEB

Ben Kluftinger explains why big pharmaceutical stocks have started to feature in WHEB's portfolio.

Only members with restricted access (ie. academics, asset owners, government and regulatory, independent advisers/trustees and sponsoring employers) can view this article. Please login or join to view.

Sign up to our newsletter